Investigating nutrient intake during use of glucagon-like peptide-1 receptor agonist: a cross-sectional study
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
Background: Glucagon-like peptide-1 receptor agonist (GLP-1RA) pharmaceutical interventions have advanced medical treatment for obesity, yet little is known about nutrient intake while using a GLP-1RA. The purpose of this study was to compare nutrient intake while using a GLP-1RA to the Dietary Reference Intakes (DRI). Methods: A cross-sectional study was conducted in a sample of participants who had been using GLP-1RA for at least one month ( N = 69). Participants answered online survey questionnaires and completed a 3-day food record. Descriptive statistics (means, standard deviations) were calculated for all participant demographic characteristics and average 3-day nutrient intakes. Average 3-day nutrient intakes were compared to the DRI using 95% confidence intervals (CI). A Bonferroni correction applied accepted significance at p ≤ 0.00156. One-way ANOVA analysis was conducted to compare the self-reported MyPlate servings to recorded servings from the 3-day food record. Results: Compared to the DRI reference values, participants consumed adequate amounts of B-vitamins, copper, phosphorus, selenium, and zinc. Participants had insufficient intakes of several key nutrients below the DRI, including fiber (14.5 g; CI: 12–17), calcium (863 mg; CI: 756–970), iron (12.1 mg; CI: 11–13), magnesium (266 mg; CI: 236–297), potassium (2,186 mg; CI: 1,969–2,402), choline (305 mg; CI: 268–342), vitamin A (560 mcg RAE; CI: 469–651), vitamin C (51 mg; CI: 41–61), vitamin D (4 mcg; CI: 3–5), vitamin E (9.6 mg; CI: 8–11), and p < 0.00156. Participants overconsumed % calories from fat (39.9%; CI: 38, 42), and saturated fat (26 g; CI: 26, 26), p < 0.00156. Participants did not meet the daily recommended MyPlate servings for fruit, vegetables, grains, or dairy ( p < 0.01). Protein intake (% total calories) was within the AMDR, however based on a g/kg/day, protein intake was significantly under daily needs. Conclusion: Participants on a GLP-1RA are not meeting the DRI for several vital nutrients through their diet or higher protein needs during weight loss. Patient-centered nutritional guidance is essential to optimize health outcomes and prevent unintended health consequences. Future large-scale studies are needed to assess the replicability of these findings and provide custom nutritional guidance for those on a GLP-1RA medication.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“72% consumed energy below estimated needs”
From Nutrition Strategies for Next‐Generation Incretin Therapies: A Systematic Scoping Review of the Current Evidence (2026) · cites this paper as [20]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A cross-sectional study of 99 participants shows that AOMs users consume an unbalanced diet, with excessive calories from saturated fatty acids, inadequate calories from carbohydrates, and a lack of micronutrients, especially vitamin D [66].”
From Nutrition and Physical Activity in Optimizing Weight Loss and Lean Mass Preservation in the Incretin-Based Medications Era: A Narrative Review (2025) · cites this paper as [66]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“According to recent studies, following AOM treatment, individuals often exhibit inadequate intake or deficiencies of several micronutrients such as retinol, vitamin E, vitamin C, magnesium, B1, B12, iron, zinc, and especially vitamin D, calcium, and B9 [66,68,74].”
From Nutrition and Physical Activity in Optimizing Weight Loss and Lean Mass Preservation in the Incretin-Based Medications Era: A Narrative Review (2025) · cites this paper as [66]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“54% consumed protein < 0.8 g/kg/day; 43% met ≥ 1.2 g/kg/day, only 10% ≥ 1.6 g/kg/day”
From Nutrition Strategies for Next‐Generation Incretin Therapies: A Systematic Scoping Review of the Current Evidence (2026) · cites this paper as [20]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The observational studies embedded within clinical trials and those using other study designs provided important insights into appetite regulation and habitual dietary intake during incretin therapy, despite the absence of structured nutrition interventions or dietitian support [5, 6, 13, 14, 20].”
From Nutrition Strategies for Next‐Generation Incretin Therapies: A Systematic Scoping Review of the Current Evidence (2026) · cites this paper as [20]
Experimental — accuracy not yet measured
21 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Dietary assessment methods in epidemiologic studies
Shim, J.-S., Oh, K., & Kim, H. C. (2014) · Epidemiology and Health · doi:10.4178/epih/e2014009 · Cited by 1,545 · cited 3×
“Dietary assessments used in research have inherent strengths and limitations (26), however, the 3-day food record was selected to help identify key knowledge gaps related to dietary intake among patients using GLP-1RA (29).”
InfluentialSubar, A. F., Kirkpatrick, S. I., Mittl, B., Zimmerman, T. P., Thompson, F. E., Bingley, C., Willis, G., Islam, N. G., Baranowski, T., McNutt, S., et al. (2012) · Journal of the Academy of Nutrition and Dietetics · doi:10.1016/j.jand.2012.04.016 · Cited by 934
Blundell, J., Finlayson, G., Axelsen, M., Flint, A., Gibbons, C., Kvist, T., & Hjerpsted, J. B. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12932 · Cited by 693 · cited 1×
“Another study evaluated ad libitum intake during week 12 of Semaglutide treatment and found a 24% reduction in total calories compared to placebo for the one-day energy intake measured in a feeding lab (23).”
Yao, H., Zhang, A., Li, D., Wu, Y., Wang, C.-Z., Wan, J.-Y., & Yuan, C.-S. (2024) · BMJ · doi:10.1136/bmj-2023-076410 · Cited by 558
Chiavaroli, L., Viguiliouk, E., Nishi, S., Blanco Mejia, S., Rahelić, D., Kahleová, H., Salas-Salvadó, J., Kendall, C., & Sievenpiper, J. (2019) · Nutrients · doi:10.3390/nu11020338 · Cited by 548
The role of protein in weight loss and maintenance
Leidy, H. J., Clifton, P. M., Astrup, A., Wycherley, T. P., Westerterp-Plantenga, M. S., Luscombe-Marsh, N. D., Woods, S. C., & Mattes, R. D. (2015) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.114.084038 · Cited by 475 · cited 2×
“Several publications emphasize the importance of and critical need for high-protein diets during weight loss (14–16).”
Lingvay, I., Cohen, R. V., Roux, C. W. L., & Sumithran, P. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01210-8 · Cited by 433
Garrow, J. S., & Summerbell, C. (1995) · PubMed · Cited by 415
Gorgojo-Martínez, J. J., Mezquita-Raya, P., Carretero-Gómez, J., Castro, A., Cebrián-Cuenca, A., de Torres-Sánchez, A., García-de-Lucas, M. D., Núñez, J., Obaya, J. C., Soler, M. J., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm12010145 · Cited by 358
Research works printed but not linked: 5
- 2024, Obesity and overweight [internet]
- 2025, Report on clinical practice guidelines for nutrition in obesity [internet]
- 2020, Dietary guidelines for Americans
- 2025, ASA24
- Wharton, 2021, Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: Recommendations for clinical practice, Postgrad Med, 134, 14, 10.1080/00325481.2021.2002616 · DOI · Paper page
Cited by
Urbina, J., Salinas‐Ruiz, L. E., Valenciano, C., & Clapp, B. (2026) · Clinical Obesity · doi:10.1111/cob.70070 · Cited by 40
“Average intakes were 60%–75% below DRI targets, with fewer than 10% of participants meeting the recommended levels [8].”
Muscle loss and GLP-1R agonists use
Rossi, G., Bucciarelli, L., Mananguite, C.-L., Giovarelli, M., & Fiorina, P. (2025) · Acta Diabetologica · doi:10.1007/s00592-025-02611-2 · Cited by 31
“…in a recent cross-sectional analysis of GLP-1RAs users, only 43% of participants achieved the minimum recommended intake of 1.2 g/kg/day, with 10% reaching higher targets such as 1.6–2.0 g /kg/day, and with an average protein consumption accounting for just 18–19% of daily energy intake [43].”
InfluentialSibal, R., Balamurugan, G., Langley, J., Graham, Y., & Mahawar, K. K. (2025) · Nutrients · doi:10.3390/nu17233659 · Cited by 30
Barrea, L., Annunziata, G., Verde, L., Galasso, M., Savastano, S., Colao, A. A. L., & Muscogiuri, G. (2025) · Current Obesity Reports · doi:10.1007/s13679-025-00667-3 · Cited by 26
“In this context, a focus on weight loss alone is not enough: MNT becomes essential to support treatment out - comes, ensuring nutritional adequacy fundamental to support metabolic health and preserve MM during semaglutide treat-ment [85 ].”
GLP-1 Receptor Agonists – Good for Body Weight, Bad for Micronutrient Status?
Kerlikowsky, F., Krämer, K., Eggersdorfer, M., & Hahn, A. (2025) · Current Developments in Nutrition · doi:10.1016/j.cdnut.2025.107587 · Cited by 18
“In addition to micronutrient status, the loss of muscle mass may be significantly higher when using GLP-1 RA than with traditional weight loss programs involving diet and exercise [35,36].”
Metadata
- Authors
- Johnson, B., Milstead, M., Thomas, O., McGlasson, T., Green, L., Kreider, R., & Jones, R.
- Corresponding author
- Johnson, Brittany
- ORCID
- Milstead, Mary
- Venue
- Frontiers in Nutrition
- Publisher
- Frontiers Media SA
- Published
- 2025-04-25
- Volume
- 12
- Pages
- 1566498-1566498
- ISSN
- 2296-861X (ISSN-L)
- PMC
- PMC12062175
- OpenAlex
- W4409825229
- Cited by
- 64
- References
- 38
- Citations by year
- 2026: 46 · 2025: 18
- FWCI
- 36.19
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Nutrition (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Nursing › Nutrition and Dietetics › Nutrition, Health and Food Behavior
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- GLP-1 receptor agonists, nutrient intake, obesity treatment, Dietary Reference Intakes, MyPlate, dietary fiber, calcium intake, iron intake, dietary magnesium, potassium intake, vitamin D, saturated fat, macronutrient distribution, food diary, micronutrient adequacy, dietary adherence, anti-obesity drugs
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Investigating nutrient intake during use of glucagon-like peptide-1 receptor agonist: a cross-sectional study. https://app.cochat.ai/papers/10.3389/fnut.2025.1566498
- The paper
- Johnson, B., Milstead, M., Thomas, O., McGlasson, T., Green, L., Kreider, R., & Jones, R. (2025). Investigating nutrient intake during use of glucagon-like peptide-1 receptor agonist: a cross-sectional study. Frontiers in Nutrition. https://doi.org/10.3389/fnut.2025.1566498
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.